Abbott Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Abbott Laboratories has a total shareholder equity of $39.0B and total debt of $14.7B, which brings its debt-to-equity ratio to 37.7%. Its total assets and total liabilities are $72.5B and $33.4B respectively. Abbott Laboratories's EBIT is $7.1B making its interest coverage ratio 27.3. It has cash and short-term investments of $6.7B.
Key information
37.7%
Debt to equity ratio
US$14.71b
Debt
| Interest coverage ratio | 27.3x |
| Cash | US$6.65b |
| Equity | US$39.04b |
| Total liabilities | US$33.42b |
| Total assets | US$72.47b |
Recent financial health updates
Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06
Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?
Nov 29We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt
Aug 13Recent updates
Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King
Dec 28Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Dec 27Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio
Dec 03Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?
Nov 29Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market
Nov 26Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?
Nov 01Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up
Oct 24Abbott: A Diversified Health Care Company With Strong Underlying Growth
Oct 20Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience
Sep 29Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price
Sep 26Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income
Sep 17We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt
Aug 13Abbott: This Dividend King Is Ready For Takeoff
Jul 31Abbott Laboratories Q2 2023 Earnings Preview: Expect Incremental Improvement
Jul 17The Big Trends: New Frontiers in Healthcare
Jul 13
Abbott Laboratories (NYSE:ABT) Is Experiencing Growth In Returns On Capital
Jul 12Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Jun 25Financial Position Analysis
Short Term Liabilities: ABT's short term assets ($22.4B) exceed its short term liabilities ($14.0B).
Long Term Liabilities: ABT's short term assets ($22.4B) exceed its long term liabilities ($19.4B).
Debt to Equity History and Analysis
Debt Level: ABT's net debt to equity ratio (20.6%) is considered satisfactory.
Reducing Debt: ABT's debt to equity ratio has reduced from 61.4% to 37.7% over the past 5 years.
Debt Coverage: ABT's debt is well covered by operating cash flow (48.6%).
Interest Coverage: ABT's interest payments on its debt are well covered by EBIT (27.3x coverage).